Abstract: Contact allergy (CA) is alteration of immune response with readiness to develop an inflammatory reaction against a specific substance of low molecular weight (hapten). The prevalence of CA is estimated at 26-40% among adults, and 21-36% children. A proportion of people with CA will remain asymptomatic, among the rest, the most frequent clinical manifestation is allergic contact dermatitis (ACD) with lifetime prevalence estimated at 10%. Less frequent manifestations include allergic contact stomatitis, conjunctivitis, vaginitis, systemic reactions, implant intolerance, and rarely urticaria, asthma, and allergic rhinitis. Patch test (epicutaneous test) is the gold standard in the diagnosis of CA and ACD: Performing the test significantly increases probability of accurate diagnosis, reduces costs of treatment, and leads to improved patients' quality of life. Patch test results may be influenced by patient's medication and health status, and interpretation requires due knowledge and experience. Other diagnostic methods are more laborious and not validated; no in vitro tests are available for routine application at present.
In Europe and most of the world, most frequent contact sensitizers are nickel, thiomersal (Merthiolate) and fragrances. Sensitization to nickel is found in 13-17% adults [16, 19] , approx. 10% adolescents [20] and 7-9% children [18, 21] . Altogether, the number of nickel-allergic people in the EU (including Bulgaria and Romania) could be estimated at 65 million, including 51 million women and 14 million men [22] . Although not all people with CA to nickel will develop symptoms of disease, the majority of them eventually will. Women are at much higher risk of acquiring allergy to nickel (20.4% versus 5.8% in men) [16] . Differences in both physiology and exposure were postulated to explain this disparity [23] . It seems, however, that the soundest explanation is the difference in exposure, especially early beginning of wearing earrings in girls. In Denmark, legal restrictions on earrings with high nickel content resulted in a 64%-decrease of the risk for nickel allergy among girls wearing earrings [24] . Encouraged by this experience and considering nickel allergy as serious burden to public health, European Parliament and European Council imposed restrictions on the marketing and use in the EU of object coming into close and prolonged contact with the skin that release large amounts of nickel (so-called "Nickel Directive"), that came fully into force in July 2001 [25] .
According to frequency of positive skin reaction on patch testing, the next rank is occupied by thiomersal (syn. Thimerosal, Thimerosol, Merthiolate). Thiomersal is used as preservative in vaccines, cosmetics and other easily spoiling products. CA to thiomersal was found in 5% adult Germans [16] . In Poland, positive patch test with this preservative was found in 8% children [21] and 18.5% young adults [20] . A possible explanation of this difference is that between the 13th and 18th year of life, repeated obligatory prophylactic vaccinations with thiomersal-preserved vaccines are carried out. This can possibly lead to alterations in the immune re-sponse. Interestingly, despite the high prevalence of contact sensitization to thiomersal and the scale of obligatory vaccination with thiomersal-containing vaccines, only a few cases of ACD caused by this preservative were reported worldwide. In 2 prospective studies, none of persons with CA to thiomersal has experienced adverse symptoms after vaccination with thiomersal-containing vaccines [26, 27] . ACD was observed only if the vaccine was administered subcutaneously (instead of the recommended intramuscular route), which underlines the importance of the skin route in the induction and elicitation of ACD. The above observations also turn attention on the question of the clinical relevance of a positive patch test result, which will be discussed later in this article.
In the above-mentioned German study of adult general population, patch tests with fragrances were positive more frequently (15.9%) than with nickel [16] . However, the test substance "fragrance mix" is not a single hapten, but mixture of 8 most frequently sensitizing fragrance compounds (Cinnamic alcohol, Cinnamic aldehyde, Hydroxycitronellal, Amylcinnamaldehyde, Geraniol, Eugenol, Isoeugenol, Oak moss absolute), and the emulsifier Sorbitan sesquioleate, each of these being a less frequent sensitizer than nickel. These and other frequent sensitizers are included into standard series that are shown in Table 1 .
DETECTING CONTACT ALLERGY
In the detection of CA, and in the diagnosis of allergic contact dermatitis (ACD), patch test is the generally-accepted method of choice and the "gold standard" [28] [29] [30] [31] . In principle, patch test relies on provoking skin inflammation (dermatitis) on a very limited skin area (less than 1 cm 2 ) under controlled conditions. Development of inflammatory reaction at the site of application of a particular substance is considered as a proof of hypersensitivity, and may also be viewed as reproduction of the disease (Fig. 1) . Thus, patch test is both a screening test and a provocation test in the target organ skin. The benefits of patch testing in patients with suspicion of ACD include reduction of the treatment cost, and increased patients' quality of life. The percentage of final diagnoses is higher among patients who had undergone patch testing (88% as compared to 69% among those non-tested). Most notably, patch tests shorten more than 20 times the time lapse from the first visit to final diagnosis (in average, from 175 days down to 8). Patch testing helps in identification and avoidance of offending haptens, thus helping in limiting symptoms of the disease. As a result, reduction of symptoms by at least 75% was observed in 66% patch-tested patients, as compared to 51% in those not tested [32] .
INDICATIONS AND CONTRAINDICATIONS FOR PATCH TESTING
Patch tests should be performed in every case of chronic and/or recurrent itchy dermatitis (eczema) or lichenification, whenever a possibility exists that CA may be the cause or a complication of the disease [33] . Thus, beside the suspicion of allergic contact dermatitis, patch tests are also indicated in a variety of inflammatory skin diseases including those regarded as "endogenous": atopic eczema, seborrheic dermatitis, stasis dermatitis, eczema around leg ulcers, irritant contact dermatitis, etc. This is due to the fact that CA, and subsequent ACD can develop as a secondary phenomenon in the course of other dermatoses -e.g. sensitization to topical therapeutics used on long-term basis in eczema or psoriasis [34, 35] . The emerging secondary ACD may complicate the course of (or even replace) the primary disease [36, 37] . Contraindications for patch testing include immune deficiencies, immunosuppressive treatment (drugs, sunbathing, sunbeds), and autoimmune diseases. Pregnancy and lactation are conditional contraindications, as there are no data on the safety of the test for the mother and child [38] .
APPLICATION OF PATCH TESTS
In a typical patch test protocol, certain amounts of suspected haptens are applied onto the skin for 48 h (24 h in some countries), and the subsequent assessment of skin reaction is done at defined time points, typically after 2, 3 and 4 days [31] . Additional reading after 7 days may reveal up to 10% positive reactions that were negative on previous checks. Examples of haptens, for which allergic skin reaction may develop later than after 4 days are: neomycin, tixocortol pivalate, and nickel [39, 40] . The test substances are applied onto the skin with the use of specially devised chambers on sticking plaster. If possible, tests should be mounted on the patient's back. Upper dorsum is the most convenient localization both for doctor and patient, and most of patch test validation was carried out in this area. Therefore, applying tests in other body areas (e.g. arms, forearms, thighs, abdomen) should be restricted to exceptional situations and should be performed by an experienced doctor due to difficulties of interpretation.
The most widely used patch test application systems worldwide are: traditional round aluminium Finn Chambers (Epitest), squaric IQ Ultra Chambers made of soft polyethylene foam (Chemotechnique Diagnostics), and TRUE Test (Thin-layer Rapid Use Epicutaneous Test, Mekos). Finn Chambers have to be filled with test substances immediately before application, while IQ Chambers may be filled immediately before testing or in advance and then stored in refrigerator for a few days. TRUE Test is loaded with haptens already during production. Material, of which the chambers are made may influence the reliability of patch tests: Finn Chambers are made of aluminium, which may come into (or catalyze) chemical reactions with test substance (e.g. with thimerosal); there is also a risk of false positive reactions in people allergic to aluminium [41, 42] . The manufacturer answered to this problem with introduction of a special series of test chambers, in which aluminium is covered by a layer of polypropylene. IQ Ultra Chambers are made of chemically inert polyethylene, which does not react with the haptens and does not sensitize patients. The shape of the test chamber may also influence the final reading: IQ Ultra Chambers and TRUE Test are squaric, which allows a better discrimination between allergic and irritant reactions. In allergic reaction, inflammatory infiltrate typically expands beyond the borders of the contact area, which can be seen as "rounding" of the testing areas' corners. In contrast, irritant reaction is typically restricted to the area of contact, so that the shape of the inflamed area remains sharp.
VEHICLES FOR TEST SUBSTANCES
White petrolatum (pet.) and water (aq.) are most frequently used vehicles (solvents) for patch test substances. In some cases, haptens are also dissolved in olive oil, rape oil, acetone, alcohol etc. Typically, 20 l of petrolatum-based test substances or 30 l of liquid preparations are loaded into chambers. The accuracy of the volume is one of the factors that determine the test's reproducibility [43] . TRUE patches are filled with test substances already during production phase, which ensures the accuracy of hapten dosage. Overall, the sensitivity of patch test is influenced by the choice of application system: Comparative studies have demonstrated that patch test applied with IQ Chamber is more sensitive than TRUE Test [44] , while TRUE Test is slightly more sensitive than patch tests with the traditional Finn Chambers [45] .
SELECTING HAPTENS FOR PATCH TESTING
Test substances should be chosen accordingly to clinical history, and include haptens suspected of provoking the disease. As not in every case the patient's history allows for identification of the offending hapten, epidemiological situation in a given geographical area or in a given risk group should also be taken into account. This means that "standard series" of haptens should be applied in every patient along with suspect substances indicated by clinical picture and history [31] . "Standard series" are collections of substances that are the most frequent sensitizers in the population of a given geographical area (e.g. country or continent) or groups of specific exposure (e.g. occupational, lifestyle, certain risk factors). Standard series are periodically updated, accordingly to recent epidemiological trends. In the past, "national" standard series were used in most countries. It does not seem reasonable anymore nowadays, in the era of globalized trade of goods, which frequently are sources of sensitizing haptens. As some intercontinental differences still are preserved, implementation of "continental series" seems most reasonable for the time being.
The most important criterion for including a hapten into a standard series is the prevalence of sensitization in the target group, which also means a chance for obtaining a positive result in a tested person. Inspired from the Pareto rule (socalled '20-80' rule), it is postulated that an "ideal standard series" should be capable of identifying offending haptens in at least 80% of ACD patients from a given population [46, 47] . It is difficult to assess whether this goal has been reached yet. In 1992, a multicenter study demonstrated that the contemporary European Standard Series (24 test substances at that time) explained only 31 -41% of all tested cases [46] . Since that time, the series was revised several times (compare the annotations in the caption for Table 1 ). After last revision in March 2008, the series consists of 28 test substances (single haptens or hapten mixtures), and has a new name "European Baseline Series" (EBS), instead of "European Standard Series" (possibly to avoid confusion of the name with industrial standards). EBS is recommended by the European Society of Contact Dermatitis (ESCD) and European Environmental Contact Dermatitis Research Group (EECDRG) as the first choice for testing patients with the suspicion of contact allergy [48] . Current listing of the EBS demonstrates that fragrances are gaining on relevance as contact sensitizers. Recent additions to the series are Fragrance mix II (Citronellal, Citral, Coumarin, Lyral, Farnesol and alpha-Hexylcinnamic aldehyde) and a separate ingredient of the mix -Lyral. Addition of these substances is expected to improve the detection rates 5% and 1.5-3%, respectively. In Table 1 , a comparison of European Baseline Series, North American Series (NAS), the International Standard Series (ISS), and TRUE Test is given. Although the latter one is not a standard series, it is cited here as an "instant" patch test product, which is quite popular among doctors who keep their contact allergy diagnostics at basic level. TRUE test is a closed system, with pre-selected 29 substances only (24 in some countries), which means that the doctor cannot adjust the selection of test substances accordingly to clinical picture and patient's history. 
INTERPRETATION OF PATCH TEST RESULTS
When a person is sensitized to a test substance, an inflammatory reaction will develop in the exposed area. The intensity of the reaction is scored and recorded according to the rules of the International Contact Dermatitis Research Group (ICDRG), presented in Table 2 and Fig. (2) . The reading and interpretation of patch results requires training and some experience. In doubtful cases, verification of the tests in a reference center may be necessary [51] . Crucial is doctor's ability to differentiate between specific allergic reactions and irritant ones, which is not always an easy task. For example, about 5% of persons tested with 1% cobalt chloride will develop local microscopic bleeding from capillary vessels (petechiae) due to the hapten's irritant properties. Inexperienced investigator might mistakenly interpret such reddish efflorescences as erythema, leading to a false conclusion of CA to cobalt. Similar changes can also be provoked by p-phenylenediamine (PPD), N-Isopropyl-N-phenyl-p-phenylenediamine (IPPD) and certain drugs [31] . In case of patch test with corticosteroids, it must be kept in mind that beside their possible allergizing potential, these substances strongly inhibit inflammatory reaction. Therefore, in case of CA to corticosteroids, positive reactions may be considerably weaker, develop with delay, and take annular shape (lower concentration, thus lower antiinflammatory effect at edges of the test area). The above are only a few examples to illustrate that interpretation of patch tests requires a good understanding of skin efflorescences, pathophysiology of the skin, as well as knowledge of pharmacological, kinetic and toxicological properties of substances tested. Therefore, reading and interpretation of patch test should be carried out by a well-trained and experienced dermatologist or allergist [52] .
DIAGNOSIS OF PHOTOALLERGIC CONTACT DERMATITIS (PACD)
In PACD, the additional factor required for the development of skin symptoms is the light, typically this is ultraviolet (UV) light. Under photoactivation, precursors are converted into offending haptens, or energy carried by the photons is necessary for initiation of binding between hapten and carrier protein. Diagnosis of photoallergic contact dermatitis requires respective modification of patch tests, i.e. irradiation of tested skin area with UV. Typically, UVA (wavelength 320-400 nm) is used; in rare cases UVB (290-320 nm) is necessary for the initiation of allergic reaction. The UVA dose used at photopatch testing is 5-10 J/cm 2 or, alternatively, of Minimal Erythema Dose (MED) determined individually for the tested person [53] . The haptens tested are applied in double sets, with only one being irradiated. While interpreting photopatch test results, both sets of haptens are compared: the "bright" side (patch tests irradiated with UV) with "dark" side (not exposed to UV). A positive result on the "bright" side with a negative result on the "dark" side suggests photoallergy, equal responses on both sides -"classical" contact allergy. Table 2 . 
CLINICAL RELEVANCE OF A POSITIVE PATCH TEST
As already mentioned, a positive result of a patch test (contact allergy) is not equivalent with the diagnosis of allergic contact dermatitis. Some persons with positive patch test result will never experience any clinical symptoms after exposure to the hapten (compare the above-discussed example of thiomersal). Therefore, the clinical relevance of positive patch test should be considered in each case. This means that the answer to the question "does the positive patch test result really explain the patient's symptoms?" should be sought for in each case. In the assessment of clinical relevance, the COADEX classification may be very helpful ( Table 3 ) [53, 54] . While interpreting patch test results, it should be also kept in mind that increasing the number of tested substances will lead to an increased risk of false positive or "accidentally positive" reactions (truly positive, yet irrelevant for present symptoms) [55] .
PATCH TESTING IN CHILDREN
CA affects 13-37% of children's general population [18] . The topic of patch testing in children is marked with conflicting views and statements, from rejection of patch testing in the early years [56, 57] , to suggestions that children can be tested already from early infancy exactly the same way as adults [58, 59] . During such discussions, a hypothetical "immune immaturity" (reduction of specific response) in the child's skin is frequently pointed on, with little scientific evidence available to support this view. In the author's opinion, it may seem somewhat illogical to assume an "immune immaturity" of child's skin for patch testing, while the skin appears "mature enough" for developing allergic skin symptoms that pose indication for patch testing. Nowadays, most authors suggest testing children with the same substances and concentrations as the adults, however, in order to tackle the technical problem of child's dorsum small size, reduced patch tests series for children were also proposed [60] . A recent study also suggested halving concentrations of certain test substances (Nickel sulfate, Formaldehyde, Carba mix, Mercaptobenzothiazole, Mercapto mix, Para-phenylenediamine, Thiuram) in children under 5 years old [61] .
LIMITATIONS OF PATCH TESTS
The specificity and sensitivity of patch tests is typically within the range of 70-80%, depending on the hapten [62] . As already mentioned, the sensitivity partly depends also on the application system. The reproducibility of patch test depends on the hapten, and is high for corticosteroids (66-100%) and nickel (80%), but relatively low (40%) for formaldehyde [63, 64] . As other clinical tests, patch tests are compromised by a range of factors, such as inter-observer variability [65] , site-tosite variability [66] , and test-to-test variability [67] . Patch test results may be furthermore influenced by the time of reading [39, 40] , quality of test substances used [68] , previous ultraviolet irradiation of the skin [69, 70] , topical and oral steroids [71, 72] , phase of menstrual cycle [73] . In some cases, excessive irritation of the skin during patch test makes the reading and interpretation difficult or impossible. This situation, referred to as "angry back" or "excited skin syndrome" should always be considered when 5 or more positive results are seen in one test series [74, 75] .
ADVERSE EFFECTS OF PATCH TESTS
Despite the fact that patch tests are relatively safe and have been used for more than a century now, one must not forget about possible adverse effects. These include a recall of active ACD in the previously involved areas, generalization of ACD, the above-mentioned "angry back syndrome", irritation of the skin by adhesive material used for mounting patch tests, and rarely contact urticaria and anaphylaxis. Individual case reports were also published of postinflammatory pigmentation disorders, scarring and development of millia in the sites of positive reactions [38] . Discussed is also the possibility of iatrogenic sensitization during patch testing, which is thought to be characterized by a very late positivization of the patch test results (10 days or more after application). However, there is so far no scientific evidence for that, and from author's experience, in some patients with late positivization, prior existence of CA to the hapten can be confirmed convincingly. Isaksson has also suggested that late appearance of the reaction is not necessarily connected to active sensitization during patch test [76] . Overall, the risk of adverse effect of patch tests is very low, provided that they are done according to expert guidelines, and tests substances are used with confirmed safety profile (e.g. diagnostic substances available commercially) [77] .
OTHER CLINICAL TESTS
The procedures described below are used when patch test results are inconclusive or contradict the clinical picture or patients' history. They should be restricted to specialized centers, as the determination of indications and contraindica- The positive test is due to cross-reaction with another hapten that is really of clinical relevance tions, and interpretation of the results require specialist knowledge and experience with the tests.
Intradermal test with haptens is considered more sensitive than patch test [78, 79] . It allows the diagnosis of CA to nickel already after 24 hours [80] . This test is considered especially helpful in the diagnosis of CA to corticosteroids [81] . Nowadays, taking into account strict regulations on the substances used in diagnosis and therapy, these tests are mainly restricted to drugs suitable for injections (antibiotics, steroids, etc.).
"Use tests" are helpful either in final confirmation of contact hypersensitivity to a hapten, or in the assessment of clinical relevance of an equivocal result of patch test (Fig. 3) . The idea behind such tests is to mimic everyday exposure to the suspected hapten in a controlled way. Several variants and names were proposed: Provocative Use Test (PUT) [82, 83] , Use Test [84] , and Repeated Open Application Test (ROAT) [83, 85] . Despite some differences, in all of these tests a small amount (0.1 ml) of patch test substance (or e.g. a cosmetic) is applied twice daily onto certain area of the skin (ulnar fossa, axilla, arm) during a period of 14-28 days. This mimics everyday exposure to a hapten better than patch test. The procedure is stopped when unequivocal symptoms of dermatitis develop in the exposed site (Fig. 4) . Use tests are laborious, time-consuming, and require a disciplined and co-operative patient. The repeated application might possibly increase the risk of iatrogenic induction, or aggravation of sensitization. Therefore, use tests should be restricted to doubtful cases, where confirmation of the sensitization promises real benefits to the patient's health.
Oral provocation test was proposed for the diagnosis of systemic ACD and pompholyx (hand and/or foot dermatitis characterized by the presence of vesicles or bullae -the allergic etiology of this disease has not been proven). Oral provocation tests have been carried out with nickel, gold, chromium, cobalt, balsam Peru, and drugs [86] [87] [88] [89] [90] [91] . A careful consideration of the possible risk versus expected benefit is required in each case, as systemic application of hapten may provoke erythroderma -a generalized inflammation of the skin that may require intensive therapy in hospital conditions.
PATCH TEST AND ATOPIC ECZEMA
For many years, a conviction that atopy and contact allergy would exclude each other was popular among some doctors and has brought much misunderstanding, as reviewed in [20] . A peculiar form of this belief was the stereotype (seemingly most popular among pediatricians) that eczema in children is always atopic (reviewed in [18] ). Some additional confusion has been added to this issue, when atopy patch test (see below) was introduced into clinical practice -a term putting together atopy and patch tests that are generally associated with CA. Recent data show convincingly that atopy and CA are independent phenomena and may either appear separately or coincide with each other [20] . CA and ACD are not uncommon in children, also in those with atopic eczema [18] . Contrary to what was suggested in the past, it appears that no modifications in the procedure are necessary when carrying out patch tests in patients with atopic eczema [92] .
ATOPY PATCH TEST
The introduction of the Atopy Patch Test (APT) has brought some confusion into the science of patch testing. The mode of application of APT is similar to "classical" Fig. (3) . Hand dermatitis in a dentist with history of improvement during holidays and relapses when at work. Patch test with dental series has demonstrated a strongly positive (++) reaction to mercury (not shown), however, no mercury-containing materials were used by the dentist at that time. After 96 hours, an atypical reaction -single, dispersed papules and vesicles, with slight erythema and no palpable infiltrate -appeared to 2-Hydroxyethylmethacrylate (HEMA, 2.0% in petrolatum, Chemotechnique Diagnostics), a dental filling material that the dentist had used in her daily practice. patch tests. Differences are in the test substances used (high molecular weight protein allergens -"atopens" instead of haptens), and the morphology of the positive patch test reaction (e.g. contact urticarial lesions, or papules at the orifices of sweat glands, which are the possible entrance for big protein allergens into the epidermis). In the last decades, publications appeared that pointed on the benefits of performing APT in atopic eczema, especially in the diagnosis of airborne dermatitis (caused e.g. by plant pollen or mites) and eczema related to food allergy [93] . In case of reading after 48 hours, the sensitivity and specificity of APT is estimated at 71-97% depending on the allergen tested [94] . However, results of large studies were also published that question the usefulness of APT in the diagnosis of atopic eczema [95] . A recent study shows satisfactory reproducibility of APT with aeroallergens in contrast to a very poor reproducibility of APT with food allergens [96] . Altogether, in contrast to "classical" patch tests, APT is not a routine diagnostic method at present, especially as regards food allergy -the official position paper of the European Academy of Allergology and Clinical Immunology (EAACI) stresses the need for further studies of the applicability of APT as a diagnostic tool [94] .
PERSPECTIVES FOR LABORATORY DIAGNOSIS
Patch tests remain the method of choice and the "gold standard" in the diagnosis of contact allergy. However, due to the previously described limitations, contraindications, and rare yet possible complications, in some patients patch test is impossible to perform, or the results are difficult to interpret. Taking this into account, a reliable in vitro test for CA would be very welcomed. Despite some promising developments [97, 98] , it seems that there is still a long way to go before a routine laboratory test for CA will be available (as reviewed in [22] ).
CONCLUSIONS

1.
The terms "contact allergy" and "allergic contact dermatitis" are not synonyms. The first term describes altered reactivity of the immune system with readiness to initiate inflammatory response to a hapten, whereas the second term refers to clinical symptoms of such inflammatory reaction in the skin.
2.
In the general population, the prevalence of contact allergy ranges from 26-40% in adults and 13-37% in children, whereas the lifetime prevalence of allergic contact dermatitis is estimated at approximately 10%.
3.
Patch test is the method of choice and the "gold standard" in the detection of contact allergy and allergic contact dermatitis. Their execution increases the probability of correct diagnosis, shortens the time lapse between first visit and final diagnosis, increases the chance for full remission, and reduces therapy Fig. (4) . In order to confirm the clinical relevance of the atypical patch test result with 2-Hydroxyethylmethacrylate (HEMA) in the patient presented in Fig. (3) , the Repeated Open Application Test (ROAT) was undertaken. Faint papules appeared after 3 days of repeated application. After a further week of repeated application, there were clear signs of dermatitis, confirming that the hand dermatitis of the dentist was indeed caused by contact with HEMA. Avoidance of the substance led to an improvement in skin condition.
costs. Altogether, patch tests help in improving patients' quality of life.
4.
The application of patch tests in not difficult, however, correct interpretation of the results requires appropriate training and experience.
